Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of advanced and unresectable ormetastatic solid malignancy

• Measurable disease as defined by RECIST v1.1, RANO, or INRC

• Performance status as follows: Participants aged ≥ 18 years: Eastern CooperativeOncology Group (ECOG) Performance Status 0-2; Participants aged 16 to < 18 years:Karnofsky score ≥ 50%; Participants aged < 16 years: Lansky score ≥ 50%

• For participants aged ≥ 18 and < 18 years: adequate hematologic and end-organfunction

• Disease progression on prior treatment, or previously untreated disease with noavailable acceptable treatment

• Adequate recovery from most recent systemic or local treatment for cancer

• Life expectancy ≥ 8 weeks

• Ability to comply with the study protocol, in the investigator's judgment

• For female participants of childbearing potential: Negative serum pregnancy test ≤ 14 days prior to initiating study treatment, agreement to remain abstinent or usesingle or combined contraception methods that result in a failure rate of < 1% peryear for the period defined in the cohort-specific inclusion criteria; and agreementto refrain from donating eggs during the same period

• For male participants: Willingness to remain abstinent or use acceptable methods ofcontraception as defined in the cohort-specific inclusion criteria

• In addition to the general inclusion criteria above, participants must meet all ofthe cohort-specific inclusion criteria for the respective cohort

Exclusion Criteria:

• Current participation or enrollment in another therapeutic clinical trial

• Any anticancer treatment within 2 weeks or 5 half-lives prior to start of studytreatment

• Whole brain radiotherapy within 14 days prior to start of study treatment

• Stereotactic radiosurgery within 7 days prior to start of study treatment

• Pregnant or breastfeeding, or intending to become pregnant during the study

• History of or concurrent serious medical condition or abnormality in clinicallaboratory tests that, in the investigator's judgment, precludes the participant'ssafe participation in and completion of the study or confounds the ability tointerpret data from the study

• Incomplete recovery from any surgery prior to the start of study treatment thatwould interfere with the determination of safety or efficacy of study treatment

• Significant cardiovascular disease, such as New York Heart Association cardiacdisease (Class II or higher), myocardial infarction, or cerebrovascular accidentwithin 3 months prior to enrollment, unstable arrhythmias, or unstable angina

• History of another active cancer within 5 years prior to screening that mayinterfere with the determination of safety or efficacy of study treatment withrespect to the qualifying solid tumor malignancy

• In addition to the general exclusion criteria above, in order to be enrolled in atreatment cohort of the study, participants must not meet any of the cohort-specificexclusion criteria